MedAustron – Austrian Hadron Therapy Centre

Slides:



Advertisements
Similar presentations
Heavy Ion Cancer Therapy
Advertisements

H. Leeb Sept 7/8, Workshop on European Small-Scale AcceleratorFacilities, Aghios Nikolaos, Crete PROPOSED PHYSICS PROGRAMME AT THE PLANNED MedAustron.
J. Feikes; Status of MLS European Synchrotron Light Source XVI. Commissioning of the Metrology Light Source in Berlin Adlershof J. Feikes for the BESSY&PTB-Commissioning.
Summary of Projects Kai Hock. LHC Upgrade About the project LHC is a 27 km circular accelerator in CERN that produces 7 TeV protons. The project is to.
TERA (Italy) – IFIC (Spain)
The CRB Project for MedAustron
Monte Carlo Based Implementation of an Energy Modulation System for Proton Therapy G.A.P. Cirrone Qualified Medical Physicist PhD Laboratori Nazionali.
GEANT4 simulation of an ocular proton beam & benchmark against MC codes D. R. Shipley, H. Palmans, C. Baker, A. Kacperek Monte Carlo 2005 Topical Meeting.
Radiobiology Annelie E. Meijer.
AUSTRON / Med - AUSTRON RECFA – Meeting Innsbruck March 26, 2004 M. Regler.
Tumour Therapy with Particle Beams Claus Grupen University of Siegen, Germany [physics/ ] Phy 224B Chapter 20: Applications of Nuclear Physics 24.
Design and test of a high-speed beam monitor for hardon therapy H. Pernegger on behalf of Erich Griesmayer Fachhochschule Wr. Neustadt/Fotec Austria (H.
PAMELA Contact Author: CONFORM is an RCUK-funded Basic Technology Programme PAMELA: Concepts Particle Accelerator for MEdicaL Applications K.Peach(JAI,
A (Quick) Survey of (Some) Medical Accelerators Dr. Todd Satogata Brookhaven National Laboratory SUNY Stony Brook PHY 684 – September 5, 2007  The NASA.
Using CERN Technologies for Medical Applications Steve Myers Director of Accelerators and Technology, Geneva, Switzerland 12th June 2013, 1.
FFAG Fixed Field Alternating Gradient synchrotrons, FFAGs, combine some of the main advantages of both cyclotrons and synchrotrons:  Fixed magnetic field.
Radiotherapy in Hungary: present status and future needs Tibor Major, PhD National Institute of Oncology Radiotherapy Department Budapest, Hungary Academia.
The ISIS strong focusing synchrotron also at the Rutherford Appleton Laboratory. Note that ISIS occupies the same hall as NIMROD used to and re- uses some.
MedAustron Dr. Peter Urschütz, EBG MedAustron GmbH
24 September 2008 ENLIGHT, ESF Workshop-Oxford European Network for Light Ion Therapy ENLIGHT Manjit Dosanjh ENLIGHT Coordinator & CERN.
The CONFORM project Roger Barlow BASROC launch 3 rd May 2007.
Cancer Therapy and Imaging Cancer Therapy and Imaging Rob Edgecock STFC Rutherford Appleton Laboratory.
CERN Medical Applications Steve Myers Head of CERN Medical Applications Former Director of Accelerators and Technology CERN, Geneva.
Crystal channeling 2009 A. Afonin, IHEP, Protvino New results of use and research of crystals at U-70. A.Afonin, IHEP, Protvino 4- th Crystal channeling.
Michael GalonskaWAO ´12, August Five years of operation at HIT Daily Performance Check & Beam Time Statistics M. Galonska, S. Scheloske, R. Cee,
March 2011 CERN, Geneva European Training Network for Particle Therapy Founded by the European Commission PARTNER.
FFAG F ixed F ield A lternating G radient Synchrotrons A new type of particle accelerator - with a wide variety of applications Cancer Therapy and UK Activities.
TPS & Simulations within PARTNER D. Bertrand, D. Prieels Valencia, SPAIN 19 JUNE 2009.
MedAustron – a case study Austrian Centre for Ion Therapy and Research oPAC 3 rd Topical Workshop on Beam Diagnostics Dr. Fadmar Osmić Accelerator Manager.
Non-scaling FFAGs in UK EMMA Requirement for (at least) one non-scaling FFAG clear: - multi-resonance crossings - huge/tiny momentum compaction - asynchronous.
Andreas Jansson, Neutrino Workshop, ANL, March 3-4, 2004 Possible beta beam scenario(s) in the US Andreas Jansson Fermilab.
Case Study Work. The problem A country does not have a hadron therapy facility. The government has been briefed that many alternative options/designs.
| kvi - center for advanced radiation technology 1 KVI-Center for Advanced Radiation Technology M.A. Hofstee 19-sep-2014 RADSAFE Kick-off, CERN.
Medical Physics at a Proton Source Proton Therapy Fast Neutron Therapy Isotope Production Basic Research AJLennox 10/08/04.
Introduction to the Non-Scaling Electron Model Rob Edgecock CCLRC Rutherford Appleton Laboratory For the EMMA Collaboration Motivation Basic EMMA parameters.
ENLIGHT,12/2/20021 Health and Science, can CERN contribute? The Mission of CERN (1954): “The Organization shall provide for collaboration among European.
Comparison of MC and TP Dosimetry Simulations for Cancer Treatment Raymond Mumme May 12, 2014 Supervisor: Thiago Lima (PhD student) Head Supervisor: Dr.
FrontierScience G.P.1 MATRIX an innovative Pixel Ionization Chamber for Online Monitoring of Hadrontherapy Treatments Giuseppe Pittà.
On behalf of the whole MedAustron Therapy Accelerator Division
Collimation in the CERN PS Booster Penny Jackson: John Adams Institute/University of Oxford/CERN This is a feasibility study.
T. Fleck, GSI, Darmstadt, Germany ICALEPCS Status of the Control System for HICAT at an advanced stage of Commissioning Functions, Restrictions.
Ghislain Roy presenting work of C. Carli, A. Garonna, D. Abler D. Kuchler, V. Toivanen, S. Myers, M. Dosanjh, S. Schuh, A. Garcia Torrico, and many others.
Photoneutron Distributions around 18 MV X-ray Radiotherapy Accelerators using Nuclear Track Detectors Fazal-ur-Rehman, H. Al-Ghamdi, M. I. Al-Jarallah.
EMMA, BASROC, Hadron Therapy and ADSRs Roger Barlow STFC Cockcroft Review Feb 11 th 2009.
Hartmut Eickhoff, GSI 1 Developments in Hadrontherapy -the role of Basic Research Institutes H. Eickhoff GSI/Darmstadt.
LOGO Status and activities of the Korea Proton Accelerator Users Association *Korea Proton Accelerator Users Association S. J. Noh Department of Applied.
The Australian Hadron Therapy and Research Facility.
1 RHIC NSRL LINAC Booster AGS Tandems STAR 6:00 o’clock PHENIX 8:00 o’clock 10:00 o’clock Polarized Jet Target 12:00 o’clock RF 4:00 o’clock (AnDY, CeC)
Beam dynamics and linac optics studies for medical proton accelerators
PSI, Zurich February 29 – March Session classification : Accelerator Concepts Tuesday, March 1, 2016 Summary Vyacheslav Yakovlev Fermilab, USA.
Plans and Activities at CERN
Present and possible future schemes for hadron therapy linacs Alberto Degiovanni for the ADAM team HG2017 Workshop , Valencia.
Proton Therapy for Cancer Treatment
Progress in the Application
Opportunities for Industry G
UNILAC requirements for BIOPHYSICS research
BEAT_PRO Beam Tailoring and procedures optimization for clinical bnct
MATerials Research: Topics and Activities
Accelerator layout > 1000 components (almost 300 magnets and power converters, 153 beam diagnostic devices, about 400m of vacuum pipes, a not neglectable.
Johannes Leidner, Fabrizio Murtas, Marco Silari
Emanuele (ESS), Alessandro (CERN), Mikel (Tekniker), Hayley (ISIS)
BIOLEIR Maurizio Vretenar on behalf of Manjit Dosanih, using slides by Silvia Schuh for the BioLEIR Study Group What does BioLEIR add capacity and capability.
HST Medical Applications
Design of a PET-isotope-based hadron therapy facility
M. D. Anderson Cancer Center Houston, TX
Progress towards Pulsed Multi-MW CERN Proton Drivers
Introduction to the Non-Scaling Electron Model
Update on Alternative Design of jleic ion injector Complex B
MEIC Alternative Design Part V
Choice of harmonic number with the consideration of ion beam formation
Presentation transcript:

MedAustron – Austrian Hadron Therapy Centre A. Fabich PP-090313-a-AFA A. Fabich MedAustron – Austrian Hadron Therapy Centre

Project MedAustron 1996-2000: PIMMS (proton and ion medical machine study) TERA, MedAustron, Oncology2000 led by CERN 2000-2004: MedAustron feasibility study in Austria 2007 Decision to finance project by Austrian Government Government of Lower Austria (warranty for € 120 Mio.) owning EBG MedAustron Federal Government of Austria (€ 41 Mio.) City of Wr. Neustadt (building site) April 2007: Foundation of EBG MedAustron GmbH EBG MedAustron constructs and operates the centre Design optimized for flexibility and requirements of users Single component tendering (no turn-key solution) PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

MedAustron - Tumour Therapy and Research Centre Medical application Tumour treatment Clinical research Non-clinical Research (NCR) Research without patients Medical Radiation Physics Radiation biology Experimental physics Beam time split Treatment:NCR about 50:50 PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Accelerator machine Developed in collaboration with CERN based on PIMMS/CNAO design Ion Sources 2 baseline sources ECR type Each suitable for both baseline ion species 1 backup source 1 branch for source research Linac Linac IH structure Output energy 7 MeV/n Synchrotron circumference 78 m to irradiation rooms PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Main Parameters – Machine and Beam Ion species: protons and carbon ions Optionally and at a later stage other ions with q/m≥1/3 are possible Intensities in irradiation room Protons: max. 1*1010 /spill Carbon ions: max. 0.4*109 /spill Tcycle ≥ 1 s, Tspill ≥ 0.1 s Energy range Proton: 60-250 MeV (medical) Higher proton energy provided for experimental physics: <800 MeV Maximum limited to 800 MeV for technical effort reasons: avoid transition crossing (at about 900 MeV proton equivalent); limit of beam rigidity at about 1.2 GeV proton equivalent Carbon: 120-400 MeV/n PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Accelerator machine (rep.) PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

CE layout PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

NCR irradiation room Experimental Physics applications Designed for research medical issues without patients experimental physics Large enough for two irradiation places Experimental Physics applications MedAustron is not a competitor with European high intensity facilities. Development and test of particle counters Preparation for test beams at high-intensity facilities with limited time slots Proton scattering facility Proton Computerized Tomography at 800 MeV Education and Training Other applications radiation damage, dosimetry, ion microprobe White book in print: “Physics opportunities at the MedAustron” PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Project Schedule CDR and CE layout frozen: spring 2008 EIA: in the course of 2009 Groundbreaking: summer 2010 Installation start: summer 2011 Commissioning start: winter 2012/2013 First patient: winter 2013/2014 PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Summary The MedAustron project is funded by the Austrian government. MedAustron will be a „state of the art“ accelerator centre for ion therapy in Austria. MedAustron will be a multi-usage facility for versatile, international research in Austria. PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Irradiation Rooms 1 2 3 4 HEBT = High Energy Transfer Line Optimized to MedAustron needs All rooms located on one side for common usage of general facility Irradiation rooms Room 1: horizontal beam line, protons/ions Used by non-clinical research Room 2: Horizontal and vertical beam line, protons/ions Used for medical treatment and Medical Radiation Physics Room 3: Horizontal line, protons/ions Used for medical treatment Room 4: Proton gantry Room 5 (extension possible): Optional ion gantry Active beam scanning on all beam lines. 1 2 3 4 PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre

Ground floor – Main area Medical office space, reception, treatment NCR technical space Accelerator Workshops … Basement General services: EL, CV ... Above synchrotron hall Power supplies Administrative office building Building above partly covering ground floor Extension possible for ion gantry PP-090313-a-AFA MedAustron – Austrian Hadron Therapy Centre